107466-55-7

Basic information

• Product Name: Butanoic acid, 4-[(2-aminobenzoyl)amino]-
• CAS NO: 107466-55-7
• Molecular Formula: C11H14N2O3
• Molecular Weight: 222.244
• Mol File: 107466-55-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Butanoic acid, 4-[(2-aminobenzoyl)amino]-(CAS DataBase Reference)
• NIST Chemistry Reference: Butanoic acid, 4-[(2-aminobenzoyl)amino]-(107466-55-7)
• EPA Substance Registry System: Butanoic acid, 4-[(2-aminobenzoyl)amino]-(107466-55-7)

Safety Data

• Hazardous Substances Data: 107466-55-7(Hazardous Substances Data)

Upstream product

• 118-48-9 isatoic anhydride 
• 56-12-2 4-amino-n-butyric acid 

Downstream Products

• 1600529-90-5 4-(2-((naphthalen-2-ylmethyl)amino)benzamido)butanoic acid 
• 1600529-89-2 4-(2-(naphthalene-2-sulfonamido)benzamido)butanoic acid 
• 1600530-05-9 4-(2-(2-(naphthalen-2-yl)acetamido)benzamido)butanoic acid 
• 1600530-04-8 4-(2-(3-phenylpropanamido)benzamido)butanoic acid 
• 1600530-03-7 4-(2-cinnamamidobenzamido)butanoic acid 
• 1600530-02-6 4-(2-(3,3-diphenylpropanamido)benzamido)butanoic acid 
• 1600531-17-6 4-(2-(2,2-diphenylacetamido)benzamido)butanoic acid 
• 1600530-01-5 4-(2-(1-naphthamido)benzamido)butanoic acid 
• 1600530-00-4 4-(2-(2-naphthamido)benzamido)butanoic acid 
• 1600529-99-4 4-(2-(thiophene-2-carboxamido)benzamido)butanoic acid 
• 1600529-98-3 4-(2-(isonicotinamido)benzamido)butanoic acid 
• 1600529-97-2 4-(2-([1,1'-biphenyl]-2-carboxamido)benzamido)butanoic acid 
• 1600529-96-1 4-(2-([1,1'-biphenyl]-3-carboxamido)benzamido)butanoic acid 
• 1600529-95-0 4-(2-([1,1'-biphenyl]-4-carboxamido)benzamido)butanoic acid 

Relevant articles and documents

Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR)

Nuclear farnesoid X receptor (FXR) has important physiological roles in various metabolic pathways including bile acid, cholesterol and glucose homeostasis. The clinical use of known synthetic non-steroidal FXR ligands is restricted due to toxicity or poor bioavailability. Here we report the development, synthesis, in vitro activity and structure-activity relationship (SAR) of anthranilic acid derivatives as novel FXR ligands. Starting from a virtual screening hit we optimized the scaffold to a series of potent partial FXR agonists with appealing drug-like properties. The most potent derivative exhibited an EC50 value of 1.5 ± 0.2 μM and 37 ± 2% maximum relative FXR activation. We investigated its SAR regarding polar interactions with the receptor by generating derivatives and computational docking.